A risk-benefit assessment of iron-chelation therapy

Drug Safety : an International Journal of Medical Toxicology and Drug Experience
J B Porter

Abstract

Iron overload caused by lifelong transfusion-dependent anaemias, such as beta-thalassaemia major, usually results in lethal cardiac toxicity in the second decade of life if not treated by iron chelation. There is no physiological mechanism for excreting the excess iron accumulated from blood transfusions and, unlike hereditary haemochromatosis, venesection is not an option. Therefore, chelation therapy is the only way to remove excess iron. This must be removed while not depriving cells of the essential iron needed for normal metabolism. Additionally, the iron chelator must prevent iron from participating in the generation of harmful free radicals. Parenteral chelation therapy with deferoxamine (desferrioxamine) is well established as promoting negative iron balance, reversing cardiac toxicity, and prolonging life expectancy well into the fourth decade of life and, most likely, beyond. Unfortunately, poor compliance with the rigours of parenteral treatment in a minority of patients limits its regular use, resulting in reduced life expectancy in these patients. Use of deferoxamine in excessive dosages may result in growth retardation, sensorineural ototoxicity and ocular toxicity, as well as bone deformities. These effects can b...Continue Reading

Citations

Dec 18, 2001·Medicinal Research Reviews·Zu D Liu, Robert C Hider
Jun 17, 2005·Documenta Ophthalmologica. Advances in Ophthalmology·Rudy R HidajatRuth L Spearing
Jun 10, 2010·Documenta Ophthalmologica. Advances in Ophthalmology·Mohamed A GeneadMartin Lindeman
Jan 5, 2002·Ophthalmology·Robert HaimoviciUNKNOWN Deferoxamine Retinopathy Study Group
Jan 5, 2002·Free Radical Biology & Medicine·Xi HuangKrystyna Frenkel
Nov 13, 2001·British Journal of Haematology·J B Porter
Jul 9, 2002·British Journal of Haematology·Adriana CeciFernando Tricta
Dec 29, 2000·Journal of Pediatric Hematology/oncology·N F OlivieriD J Weatherall
Jul 25, 2012·Indian Journal of Ophthalmology·Sumu SimonJagjit S Gilhotra
Nov 24, 2004·Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie·Peter J KertesStuart G Coupland
Jun 1, 2005·Brain & Development·Marina EconomouMiranda Athanassiou-Metaxa
Mar 7, 2012·Dalton Transactions : an International Journal of Inorganic Chemistry·Tao ZhouRobert C Hider
Jul 8, 1999·The New England Journal of Medicine·N F Olivieri
Oct 3, 2003·Expert Opinion on Pharmacotherapy·Adriana CeciDomenico De Mattia
Jan 5, 2001·Expert Opinion on Investigational Drugs·D R Richardson
Jul 31, 2009·Drug Delivery·Tayebeh ToliyatZeinab Khorasanirad
Dec 22, 1999·Drug Development and Industrial Pharmacy·N LowtherY Jin
Aug 10, 2000·Journal of Toxicology. Clinical Toxicology·J E MataP L Iversen
Jun 6, 2006·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Marjorie S FriesenRobert D Gair
Mar 17, 2007·Scandinavian Journal of Clinical and Laboratory Investigation·E TheodorssonT A Hagve
Apr 1, 2006·Brain & Development·Dimitrios I ZafeiriouMiranta Athanasiou-Metaxa
Jul 17, 2015·Molecular Pharmaceutics·Liane SchusterHanna Hartmann
Jul 11, 2012·Pharmaceutical Biology·Heshmatollah AlinezhadSeyed Mohammad Nabavi
Jul 20, 2002·Blood Reviews·L Merson, N Olivier
Jul 15, 2015·BioMed Research International·Maura Di NicolaFrancesco Viola
Jan 30, 2015·The Journal of Pharmacy and Pharmacology·Kanjana PangjitSomdet Srichairatanakool
Apr 24, 2010·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Jeff J GuoDennis W Raisch
Oct 12, 2000·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·U AmbrosettiM D Cappellini
Jul 9, 2016·BMC Ophthalmology·Aliki LiaskaIlias Georgalas
Jan 19, 2000·The Journal of Laboratory and Clinical Medicine·P R DragstenB E Hedlund
Nov 5, 1999·Carcinogenesis·K Kramer-SticklandG T Bowden
Jun 27, 2003·American Journal of Hematology·Timothy B Chaston, Des R Richardson
May 23, 2003·Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry·Timothy B Chaston, Des R Richardson
Feb 28, 2004·Blood·Melody J CunninghamUNKNOWN Thalassemia Clinical Research Network
Jun 27, 2003·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·George J KontoghiorghesAnnita Kolnagou
Oct 24, 2018·Pharmaceuticals·Marco T Nuñez, Pedro Chana-Cuevas
Dec 20, 2020·International Journal of Environmental Research and Public Health·Hani T FadelAhmed M Tarawah
Jan 6, 2021·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Dinkar KulshreshthaMandar Jog

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.